Abstract
<b>Schneider <i>et al</i>. add to the growing evidence that dupilumab is very effective in N-ERD inducing increased tolerance to ASA in 57% of patients (complete in 23%), accompanied by improvements in both upper and lower airway clinical features of disease</b>https://bit.ly/3jqs1DC
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
